CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. CRISPR Therapeutics (NASDAQ: ...

CRISPR stocks are high risk but hold potential for aggressive investors. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have the only approved CRISPR therapy. Several other biotech ...

CRISPR Therapeutics' gene therapy Casgevy obtained two approvals within the past year. The treatment could generate billions in revenue and provide a big boost for CRISPR and its development partner, ...

CRISPR Therapeutics (NASDAQ: CRSP) is gaining in prominence. The gene-editing specialist has made tremendous clinical and regulatory progress since its 2016 initial public offering, leading to ...

CRISPR Therapeutics AG (NASDAQ:CRSP) shares ended trading in the red for the eighth consecutive day on Friday. Stock closed down 0.57% at $78.92. CRSP has risen 28.99% YTD, as compared to the broader ...

CRISPR/Cas9 technology allows for precise editing of DNA, potentially treating human diseases by replacing entire genes. CRISPR Therapeutics has developed the first FDA-approved ex vivo CRISPR/Cas9 ...